Anticonvulsant activity of Aconitum violaceum against Maximal Electroshock induced seizure model
-
1
University of Karachi, Neuropharmacology Unit, Pakistan
Aconitum violaceum which is commonly found in Asia, is selected for bioassay-guided isolation of natural products. Different fractions isolated from the Aconitum violaceum is tested for anticonvulsant activity against MES Test.
Method: Animals were divided in seven groups with 6 animals in each group. The saline (vehicle control), phenytoin (20 mg/kg), AV EtAc (50mg/kg), AV MtAc (100 mg/kg) and AV Ia, AV Ib and AV Ic (50 mg/kg, 85 mg/kg and 100 mg/kg) were administered interaperitoneally to Group 1 Group II, Group III, Group IV, Groups V-VII respectively. However, a current of 80mA for 1-2 s via ear electrode is given to animals in each group. The drugs and AV fractions were administered 30 minutes before given the current. Results: All the fractions isolated from Aconitum violaceum have retarded the hind limb tonic extension and the results are comparable with phenytoin group. Whereas saline group is failed to abolish the HLTE induced by MES test.
Conclusion:Based on the obtained results we may conclude that Aconitum violaceum possesses the anticonvulsant constituent that may serve as future antiepileptic drug.
Conference:
41st European Brain and Behaviour Society Meeting, Rhodes Island, Greece, 13 Sep - 18 Sep, 2009.
Presentation Type:
Poster Presentation
Topic:
Poster presentations
Citation:
Liaquat Raza
M,
Zeeshan
M,
Ahmad
A,
Shaheen
F and
Simjee
SU
(2009). Anticonvulsant activity of Aconitum violaceum against Maximal Electroshock induced seizure model.
Conference Abstract:
41st European Brain and Behaviour Society Meeting.
doi: 10.3389/conf.neuro.08.2009.09.272
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
12 Jun 2009;
Published Online:
12 Jun 2009.
*
Correspondence:
Muhammad Liaquat Raza, University of Karachi, Neuropharmacology Unit, Karachi, Pakistan, liaquathej@yahoo.com